Abstract
Alzheimer's disease (AD) is a neurodegenerative disease and one of the leading
causes of progressive dementia, affecting 50 million people worldwide. Many pathogenic
processes, including amyloid β aggregation, tau hyperphosphorylation, oxidative stress,
neuronal death, and deterioration of the function of cholinergic neurons, are associated
with its progression. The one-compound-one-target treatment paradigm was unsuccessful
in treating AD due to the multifaceted nature of Alzheimer's disease. The recent development
of multitarget-directed ligand research has been explored to target the complementary
pathways associated with the disease. We aimed to find the key role and progress of
MTDLs in treating AD; thus, we searched for the past ten years of literature on “Pub-
Med”, “ScienceDirect”, “ACS” and “Bentham Science” using the keywords neurodegenerative
diseases, Alzheimer’s disease, and multitarget-directed ligands. The literature was
further filtered based on the quality of work and relevance to AD. Thus, this review highlights
the current advancement and advantages of multitarget-directed ligands over traditional
single-targeted drugs and recent progress in their development to treat AD.
Keywords:
Neurodegenerative diseases, Alzheimer's disease, dementia, multitarget-directed ligands, brain, amyloid protein.
[28]
Rui, W.; Reddy, H. Role of glutamate and NMDA receptors in Alzheimer’s disease. J. Alzheimers Dis., 2017, 57, 1041-1048.
[40]
Basi, G.S.; Hemphill, S.; Brigham, E.F.; Liao, A.; Aubele, D.L.; Baker, J.; Barbour, R.; Bova, M.; Chen, X.H.; Dappen, M.S.; Eichenbaum, T.; Goldbach, E.; Hawkinson, J.; Lawler-Herbold, R.; Hu, K.; Hui, T.; Jagodzinski, J.J.; Keim, P.S.; Kholodenko, D.; Latimer, L.H.; Lee, M.; Marugg, J.; Mattson, M.N.; McCauley, S.; Miller, J.L.; Motter, R.; Mutter, L.; Neitzel, M.L.; Ni, H.; Nguyen, L.; Quinn, K.; Ruslim, L.; Semko, C.M.; Shapiro, P.; Smith, J.; Soriano, F.; Szoke, B.; Tanaka, K.; Tang, P.; Tucker, J.A.; Ye, X.M.; Yu, M.; Wu, J.; Xu, Y.; Garofalo, A.W.; Sauer, J.M.; Konradi, A.W.; Ness, D.; Shopp, G.; Pleiss, M.A.; Freedman, S.B.; Schenk, D. Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer’s disease.
Alzheimers Res. Ther., 2010,
2(6), 36.
[
http://dx.doi.org/10.1186/alzrt60] [PMID:
21190552]
[52]
Cuadrado-tejedor, M.; Franco, R. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem. Neurosci., 2012, 2012(3), 832-844.
[56]
Lim, G.P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K.H.; Frautschy, S.A.; Cole, G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J. Neurosci., 2000, 20, 5709-5714.
[67]
Lill, C.M.; Rengmark, A.; Pihlstrøm, L.; Fogh, I.; Shatunov, A.; Sleiman, P.M.; Wang, L.S.; Liu, T.; Lassen, C.F.; Meissner, E.; Alexopoulos, P.; Calvo, A.; Chio, A.; Dizdar, N.; Faltraco, F.; Forsgren, L.; Kirchheiner, J.; Kurz, A.; Larsen, J.P.; Liebsch, M.; Linder, J.; Morrison, K.E.; Nissbrandt, H.; Otto, M.; Pahnke, J.; Partch, A.; Restagno, G.; Rujescu, D.; Schnack, C.; Shaw, C.E.; Shaw, P.J.; Tumani, H.; Tysnes, O.B.; Valladares, O.; Silani, V.; Berg, L.H.; Rheenen, W.; Veldink, J.H.; Lindenberger, U.; Steinhagen-Thiessen, E.; Teipel, S.; Perneczky, R.; Hakonarson, H.; Hampel, H.; Arnim, C.A.F.; Olsen, J.H.; Van Deerlin, V.M.; Al-Chalabi, A.; Toft, M.; Ritz, B.; Bertram, L. The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease.
Alzheimers Dement., 2015,
11(12), 1407-1416.
[
http://dx.doi.org/10.1016/j.jalz.2014.12.009] [PMID:
25936935]
[78]
Álvarez, X.A.; Linares, C.; Masliah, E. Combination drug therapy for the treatment of Alzheimer’s disease. Eur. Neurol. Rev., 2012, 7, 23-25.
[112]
Piazzi, L.; Cavalli, A.; Colizzi, F.; Belluti, F.; Bartolini, M.; Mancini, F.; Recanatini, M.; Andrisano, V.; Rampa, A. Multi-target-directed coumarin derivatives : HAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg. Med. Chem. Lett., 2008, 18, 423-426.
[132]
Wen-Juan, H.; Xia, L.Z.; Jia-cheng, S.; Jia-li, C.; Zhi-qiang, S. Synthesis and evaluation of coumarin/1,2,4-oxadiazole hybrids as selective BChE inhibitors with neuroprotective activity. J. Asian Nat. Prod. Res., 2018, 6020, 1-14.
[155]
Azmy, E.M.; Nassar, I.F. New Indole Derivatives as Multitarget Anti-Alzheimer’s Agents : Synthesis; Biological Evaluation and Molecular Dynamics, 2023.
[167]
Rogers, S.L.; Farlow, M.R.; Doody, R.S.; Mohs, R.; Friedhoff, L.T. Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology, 1989, 50(1), 136-145.
Download PDF Flyer